Nontraditional Risk Factors for Cardiovascular Disease in Diabetes
V. Fonseca,
C. Desouza,
S. Asnani and
I. Jialal
Section of Endocrinology (V.F., C.D., S.A.), Department of Medicine, Tulane University Medical Center, New Orleans, Louisiana 70112; and Laboratory for Atherosclerosis and Metabolic Research (I.J.), University of California Davis, Sacramento, California 95817
Correspondence: Address all correspondence and requests for reprints to: Vivian A. Fonseca, M.D., Professor of Medicine, Director, Tulane Diabetes Program, Department of Medicine, Section of Endocrinology, Tulane University Medical Center SL53, 1430 Tulane Avenue, New Orleans, Louisiana 70112-2699. E-mail: vfonseca{at}tulane.edu
People with type 2 diabetes are disproportionately affectedby cardiovascular disease (CVD), compared with those withoutdiabetes. Traditional risk factors do not fully explain thisexcess risk, and other "nontraditional" risk factors may beimportant. This review will highlight the importance of nontraditionalrisk factors for CVD in the setting of type 2 diabetes and discusstheir role in the pathogenesis of the excess CVD morbidity andmortality in these patients. We will also discuss the impactof various therapies used in patients with diabetes on nontraditionalrisk factors.
This article has been cited by other articles:
M. Anselmino, M. Wallander, A. Norhammar, L. Mellbin, and L. Ryden Implications of abnormal glucose metabolism in patients with coronary artery disease
Diabetes and Vascular Disease Research,
November 1, 2008;
5(4):
285 - 290.
[Abstract][PDF]
M. Wallander, A. Norhammar, K. Malmberg, J. Ohrvik, L. Ryden, and K. Brismar IGF Binding Protein 1 Predicts Cardiovascular Morbidity and Mortality in Patients With Acute Myocardial Infarction and Type 2 Diabetes
Diabetes Care,
September 1, 2007;
30(9):
2343 - 2348.
[Abstract][Full Text][PDF]
R. Muniyappa, M. Montagnani, K. K. Koh, and M. J. Quon Cardiovascular Actions of Insulin
Endocr. Rev.,
August 1, 2007;
28(5):
463 - 491.
[Abstract][Full Text][PDF]
R. De Caterina, R. Madonna, A. Bertolotto, and E. B. Schmidt n-3 Fatty Acids in the Treatment of Diabetic Patients: Biological rationale and clinical data
Diabetes Care,
April 1, 2007;
30(4):
1012 - 1026.
[Full Text][PDF]
K. H. Treiber, D. S. Kronfeld, and R. J. Geor Insulin Resistance in Equids: Possible Role in Laminitis
J. Nutr.,
July 1, 2006;
136(7):
2094S - 2098S.
[Abstract][Full Text][PDF]
R. Agarwal Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy
Am J Physiol Renal Physiol,
March 1, 2006;
290(3):
F600 - F605.
[Abstract][Full Text][PDF]
A. Jawa, S. Nachimuthu, M. Pendergrass, S. Asnani, and V. Fonseca Impaired Vascular Reactivity in African-American Patients with Type 2 Diabetes Mellitus and Microalbuminuria or Proteinuria Despite Angiotensin-Converting Enzyme Inhibitor Therapy
J. Clin. Endocrinol. Metab.,
January 1, 2006;
91(1):
31 - 35.
[Abstract][Full Text][PDF]
V. Fonseca, A. Jawa, and S. Asnani The PROactive Study--The Glass Is Half Full
J. Clin. Endocrinol. Metab.,
January 1, 2006;
91(1):
25 - 27.
[Full Text][PDF]
L. Ibanez, A. M. Jaramillo, A. Ferrer, and F. de Zegher High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception
Hum. Reprod.,
September 1, 2005;
20(9):
2457 - 2462.
[Abstract][Full Text][PDF]
V. A. Fonseca, J. Diez, and D. B. McNamara Decreasing Restenosis Following Angioplasty: The potential of peroxisome proliferator-activated receptor {gamma} agonists
Diabetes Care,
November 1, 2004;
27(11):
2764 - 2766.
[Full Text][PDF]
F. B. Stentz, G. E. Umpierrez, R. Cuervo, and A. E. Kitabchi Proinflammatory Cytokines, Markers of Cardiovascular Risks, Oxidative Stress, and Lipid Peroxidation in Patients With Hyperglycemic Crises
Diabetes,
August 1, 2004;
53(8):
2079 - 2086.
[Abstract][Full Text][PDF]
